Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

Looking ahead, future directions in light chain (AL) amyloidosis involve crucial advancements. With the need for improved outcomes, priorities include enhancing early diagnosis through artificial intelligence and machine learning, reducing the educational gap, and increasing awareness. Antifibril agents, particularly chimeric antigen receptor T cells and bispecifics, are emerging as promising therapies, leveraging the success seen in myeloma treatments. Notably, the use of venetoclax and Bcl-2 inhibitors holds promise, especially for patients with the translocation(11;14), constituting around 50% of AL amyloidosis cases. A critical goal is the expansion of the therapeutic landscape, with focus on deep hematologic responses achievable with small doses of innovative agents.

Additionally, advancements in diagnostic tools are anticipated, such as better imaging modalities for assessing organ involvement. The amyloid community looks forward to the results of ongoing studies and the potential incorporation of antifibril strategies. Notably, a new amyloid assay aims to identify patients and predict toxicity or mortality risk. With these developments, there is optimism about chipping away at the challenges faced within the first 100 days of treatment, offering hope for improved outcomes in the amyloidosis patient population.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.